16.32 USD
-0.11 (-0.67%)
Last: Feb 9, 2026, 09:48 AM
Overall ADMA gets a fundamental rating of 7 out of 10. We evaluated ADMA against 523 industry peers in the Biotechnology industry. While ADMA has a great health rating, its profitability is only average at the moment. ADMA is growing strongly while it is still valued neutral. This is a good combination! This makes ADMA very considerable for growth investing!
1. Profitability
1.1 Basic Checks
- In the past year ADMA was profitable.
- In the past year ADMA had a positive cash flow from operations.
- ADMA had negative earnings in 4 of the past 5 years.
- The reported operating cash flow has been mixed in the past 5 years: ADMA reported negative operating cash flow in multiple years.
1.2 Ratios
- ADMA's Return On Assets of 36.83% is amongst the best of the industry. ADMA outperforms 98.85% of its industry peers.
- ADMA has a Return On Equity of 48.57%. This is amongst the best in the industry. ADMA outperforms 98.66% of its industry peers.
- ADMA has a Return On Invested Capital of 25.76%. This is amongst the best in the industry. ADMA outperforms 98.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROIC | 25.76% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ADMA's Profit Margin of 42.87% is amongst the best of the industry. ADMA outperforms 98.09% of its industry peers.
- ADMA's Operating Margin of 34.19% is amongst the best of the industry. ADMA outperforms 97.32% of its industry peers.
- The Gross Margin of ADMA (54.71%) is better than 76.67% of its industry peers.
- ADMA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ADMA has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- Compared to 1 year ago, ADMA has more shares outstanding
- Compared to 5 years ago, ADMA has more shares outstanding
- ADMA has a better debt/assets ratio than last year.
2.2 Solvency
- ADMA has an Altman-Z score of 19.10. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 19.10, ADMA belongs to the top of the industry, outperforming 88.91% of the companies in the same industry.
- The Debt to FCF ratio of ADMA is 1.78, which is an excellent value as it means it would take ADMA, only 1.78 years of fcf income to pay off all of its debts.
- With an excellent Debt to FCF ratio value of 1.78, ADMA belongs to the best of the industry, outperforming 93.69% of the companies in the same industry.
- ADMA has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
- ADMA has a Debt to Equity ratio of 0.16. This is in the lower half of the industry: ADMA underperforms 64.24% of its industry peers.
- Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Altman-Z | 19.1 |
ROIC/WACC2.06
WACC12.5%
2.3 Liquidity
- ADMA has a Current Ratio of 7.13. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
- ADMA has a better Current ratio (7.13) than 70.94% of its industry peers.
- ADMA has a Quick Ratio of 3.65. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
- ADMA's Quick ratio of 3.65 is in line compared to the rest of the industry. ADMA outperforms 46.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 |
3. Growth
3.1 Past
- ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.86%, which is quite impressive.
- The Revenue has grown by 27.62% in the past year. This is a very strong growth!
- Measured over the past years, ADMA shows a very strong growth in Revenue. The Revenue has been growing by 70.84% on average per year.
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
3.2 Future
- The Earnings Per Share is expected to grow by 33.00% on average over the next years. This is a very strong growth
- Based on estimates for the next years, ADMA will show a very strong growth in Revenue. The Revenue will grow by 21.50% on average per year.
EPS Next Y19.34%
EPS Next 2Y35.12%
EPS Next 3Y33.64%
EPS Next 5Y33%
Revenue Next Year20.85%
Revenue Next 2Y22.49%
Revenue Next 3Y22.24%
Revenue Next 5Y21.5%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- ADMA is valuated quite expensively with a Price/Earnings ratio of 30.22.
- 93.12% of the companies in the same industry are more expensive than ADMA, based on the Price/Earnings ratio.
- ADMA's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.93.
- The Price/Forward Earnings ratio is 17.88, which indicates a rather expensive current valuation of ADMA.
- Based on the Price/Forward Earnings ratio, ADMA is valued cheaper than 94.26% of the companies in the same industry.
- ADMA's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.77.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.22 | ||
| Fwd PE | 17.88 |
4.2 Price Multiples
- 93.69% of the companies in the same industry are more expensive than ADMA, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, ADMA is valued cheaply inside the industry as 91.40% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 95.65 | ||
| EV/EBITDA | 22.41 |
4.3 Compensation for Growth
- ADMA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- The decent profitability rating of ADMA may justify a higher PE ratio.
- ADMA's earnings are expected to grow with 33.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.56
PEG (5Y)N/A
EPS Next 2Y35.12%
EPS Next 3Y33.64%
5. Dividend
5.1 Amount
- No dividends for ADMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:ADMA (2/9/2026, 9:48:53 AM)
16.32
-0.11 (-0.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-02 2026-03-02/amc
Inst Owners93.5%
Inst Owner Change-3.36%
Ins Owners2.35%
Ins Owner Change-0.33%
Market Cap3.88B
Revenue(TTM)488.56M
Net Income(TTM)209.45M
Analysts82.22
Price Target26.18 (60.42%)
Short Float %8.13%
Short Ratio7.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.96%
Min EPS beat(2)-1.96%
Max EPS beat(2)-1.96%
EPS beat(4)0
Avg EPS beat(4)-10.9%
Min EPS beat(4)-31.17%
Max EPS beat(4)-1.96%
EPS beat(8)3
Avg EPS beat(8)-42.78%
EPS beat(12)6
Avg EPS beat(12)-7.71%
EPS beat(16)8
Avg EPS beat(16)-5.59%
Revenue beat(2)1
Avg Revenue beat(2)-0.85%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)0.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)2.16%
Revenue beat(8)6
Avg Revenue beat(8)4.26%
Revenue beat(12)10
Avg Revenue beat(12)4.8%
Revenue beat(16)14
Avg Revenue beat(16)6.2%
PT rev (1m)0%
PT rev (3m)-5.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.89%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.4%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)-0.21%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)0.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.22 | ||
| Fwd PE | 17.88 | ||
| P/S | 7.95 | ||
| P/FCF | 95.65 | ||
| P/OCF | 59.78 | ||
| P/B | 9.01 | ||
| P/tB | 9.09 | ||
| EV/EBITDA | 22.41 |
EPS(TTM)0.54
EY3.31%
EPS(NY)0.91
Fwd EY5.59%
FCF(TTM)0.17
FCFY1.05%
OCF(TTM)0.27
OCFY1.67%
SpS2.05
BVpS1.81
TBVpS1.79
PEG (NY)1.56
PEG (5Y)N/A
Graham Number4.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROCE | 32.61% | ||
| ROIC | 25.76% | ||
| ROICexc | 29.27% | ||
| ROICexgc | 29.53% | ||
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% | ||
| FCFM | 8.31% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score7
Asset Turnover0.86
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Debt/EBITDA | 0.4 | ||
| Cap/Depr | 304.79% | ||
| Cap/Sales | 4.99% | ||
| Interest Coverage | 15.23 | ||
| Cash Conversion | 37.13% | ||
| Profit Quality | 19.39% | ||
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 | ||
| Altman-Z | 19.1 |
F-Score7
WACC12.5%
ROIC/WACC2.06
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y19.34%
EPS Next 2Y35.12%
EPS Next 3Y33.64%
EPS Next 5Y33%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
Revenue Next Year20.85%
Revenue Next 2Y22.49%
Revenue Next 3Y22.24%
Revenue Next 5Y21.5%
EBIT growth 1Y45.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.1%
EBIT Next 3Y45.85%
EBIT Next 5Y36.27%
FCF growth 1Y272.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y501.56%
OCF growth 3YN/A
OCF growth 5YN/A
ADMA BIOLOGICS INC / ADMA FAQ
What is the fundamental rating for ADMA stock?
ChartMill assigns a fundamental rating of 7 / 10 to ADMA.
What is the valuation status of ADMA BIOLOGICS INC (ADMA) stock?
ChartMill assigns a valuation rating of 6 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Fairly Valued.
How profitable is ADMA BIOLOGICS INC (ADMA) stock?
ADMA BIOLOGICS INC (ADMA) has a profitability rating of 6 / 10.
What is the financial health of ADMA BIOLOGICS INC (ADMA) stock?
The financial health rating of ADMA BIOLOGICS INC (ADMA) is 8 / 10.